Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
We announced today that the Company is securing up to €47.5 million. The funds will be used to carry out eyonis™ LCS SaMD FDA regulatory approval and CE mark and for completing ongoing active commercialization partnership discussions with leading US providers of AI diagnostics https://t.co/LH8D8LwdMu
Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU https://t.co/ac4kA4qSRd https://t.co/i0RRiYOL8Y
Sycai Medical, startup tecnológica del sector sanitario, cierra ronda de inversión de tres millones de euros para el desarrollo de su dispositivo médico, basado en inteligencia artificial, que detecta el #cáncer y las #lesiones premalignas en el abdomen. Santiago Millán…
Sycai Medical has successfully raised €3 million in a funding round aimed at developing an artificial intelligence-based medical device for the detection of pancreatic cancer and premalignant lesions in the abdomen. The investment will support the startup's efforts in enhancing cancer screening technologies. Meanwhile, Median Technologies has announced it is securing up to €47.5 million to facilitate regulatory filings and commercialization of its AI lung cancer diagnostic device, eyonis™, in the U.S. and EU markets. This funding will also aid in obtaining FDA regulatory approval and CE marking, alongside ongoing discussions for commercialization partnerships with leading U.S. AI diagnostic providers.
